Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial.

Yatham LN, Vieta E, Goodwin GM, Bourin M, de Bodinat C, Laredo J, Calabrese J; Agomelatine Study Group.

Br J Psychiatry. 2016 Jan;208(1):78-86. doi: 10.1192/bjp.bp.114.147587. Epub 2015 May 21.

PMID:
25999335
2.

Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.

Stein DJ, Ahokas A, Márquez MS, Höschl C, Oh KS, Jarema M, Avedisova AS, Albarran C, Olivier V.

J Clin Psychiatry. 2014 Apr;75(4):362-8. doi: 10.4088/JCP.13m08433.

PMID:
24569045
3.

A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.

Kennedy SH, Avedisova A, Giménez-Montesinos N, Belaïdi C, de Bodinat C; Agomelatine Study Group.

Eur Neuropsychopharmacol. 2014 Apr;24(4):553-63. doi: 10.1016/j.euroneuro.2014.01.006. Epub 2014 Jan 31.

PMID:
24530273
4.

The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study.

Heun R, Ahokas A, Boyer P, Giménez-Montesinos N, Pontes-Soares F, Olivier V; Agomelatine Study Group.

J Clin Psychiatry. 2013 Jun;74(6):587-94. doi: 10.4088/JCP.12m08250.

PMID:
23842010
5.

Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.

Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C.

J Clin Psychiatry. 2012 Jul;73(7):1002-8. doi: 10.4088/JCP.11m07493.

PMID:
22901350
6.

Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.

Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H.

Int J Neuropsychopharmacol. 2010 Apr;13(3):305-20. doi: 10.1017/S1461145709990423. Epub 2009 Aug 20.

PMID:
19691907
7.

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.

Goodwin GM, Emsley R, Rembry S, Rouillon F; Agomelatine Study Group.

J Clin Psychiatry. 2009 Aug;70(8):1128-37. doi: 10.4088/JCP.08m04548. Epub 2009 Aug 11.

PMID:
19689920
8.

The DSM-IV-based Generalized Anxiety Disorder Severity Scale: preliminary validation using data from a trial of agomelatine versus placebo.

Stein DJ, Fincham D, Seedat S, de Bodinat C, Ahokas A.

J Nerv Ment Dis. 2009 Jun;197(6):391-4. doi: 10.1097/NMD.0b013e3181a77152.

PMID:
19525737
9.

Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.

Stein DJ, Ahokas AA, de Bodinat C.

J Clin Psychopharmacol. 2008 Oct;28(5):561-6. doi: 10.1097/JCP.0b013e318184ff5b.

PMID:
18794654
10.

Determinants of personal and indoor PM2.5 and absorbance among elderly subjects with coronary heart disease.

Lanki T, Ahokas A, Alm S, Janssen NA, Hoek G, De Hartog JJ, Brunekreef B, Pekkanen J.

J Expo Sci Environ Epidemiol. 2007 Mar;17(2):124-33. Epub 2006 Jan 25.

PMID:
16519413
11.

Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study.

Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T.

Br J Psychiatry. 2005 Oct;187:352-9.

12.

Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.

Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J; Deramciclane Dose-Finding Study Group.

Eur Neuropsychopharmacol. 2005 Dec;15(6):617-23. Epub 2005 Jun 9.

PMID:
15949921
13.

Neopterin and macrophage inflammatory protein-1alpha in the cerebrospinal fluid of schizophrenic patients: no evidence of intrathecal inflammation.

Nikkilä HV, Ahokas A, Wahlbeck K, Rimón R, Andersson LC.

Neuropsychobiology. 2002;46(4):169-72.

PMID:
12566931
14.

Dropout rates in randomised antipsychotic drug trials.

Wahlbeck K, Tuunainen A, Ahokas A, Leucht S.

Psychopharmacology (Berl). 2001 May;155(3):230-3.

PMID:
11432684
15.
16.

Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia.

Nikkilä HV, Müller K, Ahokas A, Rimón R, Andersson LC.

Schizophr Res. 2001 Apr 15;49(1-2):99-105.

PMID:
11343869
17.

Mitchell B. Balter Award. Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia.

Lahdelma L, Ahokas A, Andersson LC, Suvisaari J, Hovatta I, Huttunen MO, Koskimies S.

J Clin Psychopharmacol. 2001 Feb;21(1):4-7.

PMID:
11199946
18.

Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.

Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimón R.

Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):911-22.

PMID:
11041534
19.

Positive treatment effect of estradiol in postpartum psychosis: a pilot study.

Ahokas A, Aito M, Rimón R.

J Clin Psychiatry. 2000 Mar;61(3):166-9.

PMID:
10817099
20.

Cerebrospinal fluid angiotensin-converting enzyme (ACE) correlates with length of illness in schizophrenia.

Wahlbeck K, Ahokas A, Nikkilä H, Miettinen K, Rimón R.

Schizophr Res. 2000 Jan 21;41(2):335-40.

PMID:
10708342
Items per page

Supplemental Content

Loading ...
Write to the Help Desk